Home › Multiple Myeloma
Multiple Myeloma clinical trials recruiting in the U.S.
238 studies for Multiple Myeloma are recruiting participants at sites across the United States.
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
Cities with the most studies
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO26 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- St. Louis, MO23 studies
- Rochester, MN23 studies
- Washington, DC22 studies
- Seattle, WA22 studies
- Edison, NJ22 studies
- Chicago, IL22 studies
- Salt Lake City, UT21 studies
- Miami, FL21 studies
- Charlotte, NC21 studies
- Milwaukee, WI21 studies
- Queens, NY20 studies
- Detroit, MI19 studies
- Jacksonville, FL18 studies
- Birmingham, AL18 studies
- Philadelphia, PA17 studies
- Los Angeles, CA17 studies
- Cincinnati, OH17 studies
- Dallas, TX17 studies
- Omaha, NE16 studies
- Cleveland, OH16 studies
- Phoenix, AZ16 studies
- San Francisco, CA15 studies
- Cedar Rapids, IA15 studies
- Tampa, FL15 studies
- New Haven, CT14 studies
- New Rochelle, NY14 studies
- Winston-Salem, NC14 studies
- Clifton, NJ14 studies
- Irvine, CA13 studies
- East Norwalk, CT13 studies
- Staten Island, NY13 studies
By state
- Alabama22 studies
- Arizona27 studies
- Arkansas9 studies
- California70 studies
- Colorado36 studies
- Connecticut18 studies
- Delaware4 studies
- District of Columbia10 studies
- Florida55 studies
- Georgia49 studies
- Idaho3 studies
- Illinois31 studies
- Indiana19 studies
- Iowa17 studies
- Kansas12 studies
- Kentucky15 studies
- Louisiana9 studies
- Maine3 studies
- Maryland25 studies
- Massachusetts44 studies
- Michigan26 studies
- Minnesota29 studies
- Missouri26 studies
- Montana4 studies
- Nebraska18 studies
- New Hampshire4 studies
- New Jersey38 studies
- New Mexico5 studies
- New York75 studies
- North Carolina52 studies
- North Dakota5 studies
- Ohio46 studies
- Oklahoma3 studies
- Oregon20 studies
- Pennsylvania24 studies
- Rhode Island6 studies
- South Carolina9 studies
- South Dakota3 studies
- Tennessee32 studies
- Texas53 studies
- Utah21 studies
- Virginia20 studies
- Washington30 studies
- West Virginia3 studies
- Wisconsin28 studies
Recently updated studies
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Sep 29, 2026 · NCT06904066Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT02682667Tissue Collection for Studies of Lymph Cancer
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT01676805A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT04973605Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06948084Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Sep 28, 2026 · NCT03412877A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05652335A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06500884A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07336472Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07609940A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05201781A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07393282A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06768489A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07258511Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Sep 25, 2026 · NCT06052826A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05552222A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07073547A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 25, 2026 · NCT07149857A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04634552A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05623020A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07477587Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06398457From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.